December 13 – Dr. Nicholas Zdenkowski
Dr. Nick Zdenkowski discusses tumor-infiltrating lymphocytes as prognostic and predictive factors in breast cancer.
December 13 – Dr. Nicholas Zdenkowski Read More »
December 13 – Dr. Virginia Kaklamani
Dr. Virginia Kaklamani discusses the PATINA trial, a phase III clinical trial.
December 13 – Dr. Virginia Kaklamani Read More »
December 13 – Dr. Nicholas Zdenkowski
Dr. Nick Zdenkowski discusses resistance mechanisms to CDK4/6 inhibitors.
December 13 – Dr. Nicholas Zdenkowski Read More »
December 13 – Dr. Virginia Kaklamani
Dr. Virginia Kaklamani highlights the EMBER-3 clinical trial, which found that imlunestrant outperformed single-agent endocrine therapy in patients with ESR1 mutations and showed improvement when combined with abemaciclib, suggesting potential FDA approval.
December 13 – Dr. Virginia Kaklamani Read More »
December 13 – Dr. Nicholas Zdenkowski
Dr. Nick Zdenkowski discusses the ZEST trial.
December 13 – Dr. Nicholas Zdenkowski Read More »
December 12 – Dr. Carlos Barrios
Dr. Carlos Barrios discusses the PATINA trial that was presented recently.
December 12 – Dr. Carlos Barrios Read More »
December 12 – Dr. Nicholas Zdenkowski
Dr. Nick Zdenkowski discusses the SUPREMO trial.
December 12 – Dr. Nicholas Zdenkowski Read More »
December 12 – Dr. Nicholas Zdenkowski
Dr. Nick Zdenkowski discusses the PATINA trial.
December 12 – Dr. Nicholas Zdenkowski Read More »
December 12 – Dr. Sherene Loi
Dr. Sherene Loi discusses the development and importance of immune biomarkers in breast cancer, highlighting the TIL biomarker, the limitations of PD-L1, and the potential of new biomarkers to refine treatment algorithms and clinical trials
December 12 – Dr. Sherene Loi Read More »
December 11 – Dr. Nicholas Zdenkowski
Dr. Nick Zdenkowski discusses the EMBER trial on second-line ER-targeted drugs, patient-reported outcome monitoring, and the survival benefits of risk-reducing surgeries for BRCA mutant patients.
December 11 – Dr. Nicholas Zdenkowski Read More »